PE ratio relative to earnings growth — is the valuation justified?
| Symbol | Company | PEG | P/E | Growth | vs MRK |
|---|---|---|---|---|---|
| GILD | Gilead Sciences, Inc. | 0.12 | 17.9 | 149.5% | -93% |
| LLY | Eli Lilly and Company | 1.49 | 41.1 | 27.5% | -9% |
| BMY | Bristol-Myers Squibb Company | 3.16 | 16.5 | 5.2% | +92% |
| AMGN | Amgen Inc. | 8.49 | 24.9 | 2.9% | +418% |
| PFE | Pfizer Inc. | 12.31 | 18.9 | 1.5% | +650% |